Regeneron's antibody drug added to UK Recovery trial of Covid treatments | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Wednesday
June 11, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
WEDNESDAY, JUNE 11, 2025
Regeneron's antibody drug added to UK Recovery trial of Covid treatments

Coronavirus chronicle

Reuters
14 September, 2020, 05:20 pm
Last modified: 14 September, 2020, 05:24 pm

Related News

  • Regeneron's Covid antibody drug shows protection for up to 8 months
  • AstraZeneca antibody cocktail succeeds in late-stage study to treat Covid-19
  • Eli Lilly's antibody combination receives FDA emergency use authorization for Covid-19
  • Regeneron announces more positive results for Covid-19 treatment
  • AstraZeneca’s Covid-19 antibody drug heads into advanced trials

Regeneron's antibody drug added to UK Recovery trial of Covid treatments

The UK RECOVERY trial, which has been testing a range of potential Covid-19 treatments since it began in April, will compare the effects of adding REGN-COV2 - a lab-manufactured monoclonal antibody - to standard care

Reuters
14 September, 2020, 05:20 pm
Last modified: 14 September, 2020, 05:24 pm
The ultrastructural morphology exhibited by the 2019 Novel Coronavirus, which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, US January 29, 2020/Reuters
The ultrastructural morphology exhibited by the 2019 Novel Coronavirus, which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, US January 29, 2020/Reuters

The world's largest randomised trial of potential medicines for Covid-19 is to add Regeneron's experimental antiviral antibody cocktail REGN-COV2 to the drugs it is testing in patients hospitalised with the disease.

The UK RECOVERY trial, which has been testing a range of potential Covid-19 treatments since it began in April, will compare the effects of adding REGN-COV2 - a lab-manufactured monoclonal antibody - to standard care.

"This is the first drug actually designed for this disease," said Martin Landray, a professor of medicine & epidemiology at Oxford University who is co-leading the trial.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

"There are lots of good reasons for thinking this might be really quite a powerful treatment," he told Reuters in an interview.

The addition of Regeneron's drug to the RECOVERY trial comes amid growing hopes that monoclonal antibodies may emerge as effective ways to treat Covid-19.

Until now, the RECOVERY trial had mostly been studying whether existing drugs could be re-purposed to tackle the new disease, and it has already found answers on a number of them.

In June and September, trial results showed that widely used steroids such as dexamethasone and hydrocortisone were able to reduce death rates among severely-ill Covid-19 patients

Also in June, RECOVERY trial results showed that the anti-malarial drug hydroxychloroquine, once touted by US President Donald Trump as a potential "game changer" in the pandemic, was of no benefit in treating Covid-19 patients.

Regeneron's REGN-COV2 cocktail, which the company is already testing in late-stage clinical trials in people, combines one Regeneron-made antibody and a second antibody isolated from people who have recovered after being infected with Covid-19.

The combination is designed to bind to the spike protein used by the new coronavirus to gain access to human cells, limiting the virus's ability to escape.

Regeneron developed the biological drug before linking up with Roche to expand its manufacturing capacity in hopes of meeting global demand, should the medicine prove effective. Regeneron would handle US sales, with Roche selling the medicine around the world.

Landray said his team had secured enough supply of the drug so that up to "several thousand" patients could be given it in the trial and compared with several thousand controls.

"Given that the second phase (of Covid-19 infections in the UK) seems to be coming now, it is a really good time to be starting this," he said.

The United States already has a $450 million deal for the cocktail in place, under the terms of which Regeneron will sell it around 70,000 to 300,000 potential treatment doses or 420,000 to 1.3 million prevention doses of REGN-COV2. Data is due later this month, Regeneron has said.

Alongside Regeneron, Eli Lilly, working with biotech firm AbCellera, is seen as a leading contender in the antibody race. In August it started testing whether its antibody can prevent Covid-19 infections in nursing homes. A separate trial testing the compound on recently diagnosed Covid patients may yield initial data in September or shortly after.

GlaxoSmithKline and partner Vir Biotechnology also began testing an experimental antibody on newly diagnosed Covid-19 patients late last month.

AstraZeneca is for now testing its antibody-based cocktail on healthy volunteers for tolerability.

Regeneron / Covid-19 Antibody Test

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Bangladesh's growth forecast unchanged: WB report
    Bangladesh's growth forecast unchanged: WB report
  • Faiz Ahmad Tayeb. Photo: BSS
    Import duty on raw materials for e-bikes, lithium batteries reduced from 80% to 1% in some cases: Faiz Taiyeb
  • Swedish activist Greta Thunberg, who departed Israel by plane on Tuesday after being detained aboard the Gaza-bound British-flagged yacht "Madleen" after Israeli forces boarded the charity vessel as it attempted to reach the Gaza Strip in defiance of an Israeli naval blockade, talks to journalists surrounded by French police as she arrives at a terminal at the Paris-Charles de Gaulle Airport, in Roissy-en-France near Paris, France, June 10, 2025. REUTERS/Gonzalo Fuentes
    Greta Thunberg says she was kidnapped by Israel in international waters

MOST VIEWED

  • On left, Abdullah Hil Rakib, former senior vice president (SVP) of BGMEA and additional managing director of Team Group; on right, Captain Md Saifuzzaman (Guddu), a Boeing 787 Dreamliner pilot for Biman Bangladesh Airlines. Photos: Collected
    Ex-BGMEA SVP Abdullah Hil Rakib, Biman 787 pilot Saifuzzaman drown in boating accident in Canada
  • File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar
    Dhaka: The city we never want to return to, but always do
  • Chief Adviser Muhammad Yunus leaves for a four-day visit to the United Kingdom from the Dhaka airport on 9 June 2025. Photo: CA Press Wing
    CA Yunus leaves for UK; discussion expected on renewable energy investment, laundered money
  • File Photo: Collected
    Enhanced surveillance at Ctg airport amid rising global Covid-19 cases
  • Inside the aid ship stormed by Israeli forces on 9 June 2025. Photo: BBC
    Israeli forces stormed aid boat carrying Greta Thunberg bound for Gaza: Freedom Flotilla Coalition
  • Photos: Collected
    Abdul Hamid wasn't arrested because he's not wanted right now: Home adviser

Related News

  • Regeneron's Covid antibody drug shows protection for up to 8 months
  • AstraZeneca antibody cocktail succeeds in late-stage study to treat Covid-19
  • Eli Lilly's antibody combination receives FDA emergency use authorization for Covid-19
  • Regeneron announces more positive results for Covid-19 treatment
  • AstraZeneca’s Covid-19 antibody drug heads into advanced trials

Features

Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

5h | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

1d | Features
Photo collage shows political posters in Bagerhat. Photos: Jannatul Naym Pieal

From Sheikh Dynasty to sibling rivalry: Bagerhat signals a turning tide in local politics

3d | Bangladesh
Illustration: TBS

Unbearable weight of the white coat: The mental health crisis in our medical colleges

6d | Panorama

More Videos from TBS

Greta Thunberg deported from Israel

Greta Thunberg deported from Israel

7h | TBS World
BNP is not a revolutionary party: Mirza Fakhrul

BNP is not a revolutionary party: Mirza Fakhrul

8h | TBS Today
News of The Day, 10 JUNE 2025

News of The Day, 10 JUNE 2025

6h | TBS News of the day
Trump sends 2,000 more National Guard and 700 Marines to Los Angeles

Trump sends 2,000 more National Guard and 700 Marines to Los Angeles

9h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net